No doubt RGBP is racing to become SEC current on all their filings that's likely a requirement for most Institutional Investors buying their stock, but also so that they can become Pink Current, get the STOP SIGN DOWN, attract a broader cross section of investors, and Up List soon to OTCBQ, and eventually to NASDAQ.
ALL of this points to the swift and forthright progress RGBP is making to secure their place in the "disruptive biotechnology" space of Pharmaceuticals as a top gainer on the OTC (short term) and Major Exchanges (long term).
IMO, easy $4-$7 by year end possibly much higher with more Institutional Investors coming on board.